Enzalutamide (Figure 4) is a second-generation anti-androgen with higher affinity for the AR than bicalutamide, and capable of retaining activity in the presence of increased AR expression, often seen in castration resistant PCa (CRPC) [76]. Here, AR is linked to posterior cortical atrophy.